A Phase 3 interventional study of Tramadol HCl/acetaminophen Extended Release and Placebo in Low Back Pain, sponsored by Janssen Korea, Ltd., Korea. Completed. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-07-24.
Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing acetaminophen in Low Back Pain — none open to participants now, none under way, none of them phase 3. Acetaminophen · Low Back Pain.
Among the 10 studies testing acetaminophen in Low Back Pain, this one is the 2nd largest by enrollment, is the only one that started in 2009, is one of 4 in phase 3, and was the 3rd registered.
2,929 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.
Browse Low Back Pain studies →None of the 10 studies testing acetaminophen in Low Back Pain is open now. The open studies under Low Back Pain, anywhere →
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 25 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 248 is above the median of 60 across 2,368 interventional studies indexed under Low Back Pain.
Median enrollment 120 across the 10 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 8 most frequent:
This study is registered under Janssen Korea, Ltd., Korea, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Korea, Ltd., Korea is the lead sponsor of 79 studies on the registry; 2 are open to participants now.
19 studies in Low Back Pain by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 19 studies in Low Back Pain by Johnson & Johnson, this one is the 9th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2009, is one of 10 in phase 3, and was the 15th registered.
Johnson & Johnson’s Low Back Pain studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing acetaminophen in Low Back Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 19 in Low Back Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of extended release (ER) tramadol hydrochloride (HCl)/acetaminophen compared with placebo in participants with chronic (lasting a long time) low-back pain.
This is a double blind (a medical research study in which neither the researchers nor the participants know what treatment the participants is receiving), randomized (study drug is assigned by chance), placebo-controlled, parallel group (a medical research study comparing the response in 2 or more groups of participants receiving different interventions [treatments]) and up-titration study in participants with chronic low back pain. The study will consist of 6 visits (Day -7 to Day -1 [Visit 1], Day 1 [Visit 2], Day 3 [telephone visit], Day 8 [Visit 3], Day 15 [Visit 4] and Day 29 [Visit 5]) and 2 phases: a screening phase and treatment phase. Screening phase will be of 7 days during which, participants will receive stable dose of non-steroidal anti-inflammatory drugs (NSAIDS) or COX-2 selective inhibitors (NSAID that specifically inhibits an enzyme known as cyclooxygenase-2) for pain therapy. On the basis of average pain intensity over the last 48 hours which will be measured at baseline (at the end of screening period), participants will enter the treatment phase. Treatment phase will be of 28 days which includes 7-days of dose titration period. In treatment phase all participants will be randomly assigned to 1 of 2 possible treatments: tramadol HCl 75 milligram (mg)/acetaminophen 650 mg ER tablet treatment or the equivalent placebo (an inactive substance) treatment until study completion, Day 29. Participants will receive 1 tablet of tramadol HCl/acetaminophen ER or its equivalent placebo, once daily for 3 days. After the first 3 days, the participants will receive a telephone inquiry monitoring the occurrence of adverse events and will be given additional administration instructions for the next 4 days (1 tablet twice daily for 4 days). From Day 7, participants will receive 1 or 2 tablets twice a day depending on the degree of pain relief required. Participants will visit the center on the Day 8 (Visit 3), Day 15 (Visit 4), and Day 29 (Visit 5) after starting study drug. The efficacy will be assessed by measuring extent of reduction in pain intensity on a Visual Analog Scale (VAS). Participants' safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 1 tablet containing fixed dose of combination of tramadol hydrochloride (HCl) 75 milligram (mg) /acetaminophen Extended Release (ER) 650 mg orally once daily on Days 1 to 3, 1 tablet twice daily (tramadol HCl 150 mg/acetaminophen 1300 mg) on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
Drug: Tramadol HCl/acetaminophen Extended Release
Prticipants will receive 1 tablet matching placebo once daily orally on Days 1 to 3, 1 tablet twice daily on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
Drug: Placebo
Drug pages: Tramadol · Acetaminophen
Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
Also known as: Ultracet Extended Relaese
Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
Drug pages: Tramadol · Acetaminophen
Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
Also known as: Ultracet Extended Relaese
Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
Percentage of Participants With Reduction in Pain Intensity
The percentage of participants with extent of reduction in pain intensity greater than or equal to 30 percent was reported. Pain intensity change rate was calculated by Visual Analog Scale (VAS) score at baseline minus VAS score at Day 29 divided by VAS score at Baseline. VAS is a 10 centimeter (cm) scale. Intensity of pain range: 0 cm=no pain to 10 cm=worst possible pain.
Time frame: Baseline up to Day 29
Change From Baseline in Pain Intensity at Day 29
Change in pain intensity experienced by participants over the last 48 hours was measured on Day 29 against Baseline with VAS. VAS is a 10 cm scale. Intensity of pain range: 0 cm=no pain to 10 cm=worst possible pain.
Time frame: Baseline and Day 29
Percentage of Participants With Pain Relief
Pain relief was measured in 6 stages to assess the participant's pain relief. Extent of pain relief was measured on a scale ranging from 4 to -1, where 4=complete disappearance, 3=fair relief, 2=moderate relief, 1=slight relief, 0=no change and -1=pain worsening. Relief more than 'slight relief (1)' was considered as pain relief success.
Time frame: Day 8, Day 15 and Day 29
Change From Baseline in Short Form (SF)-36 Score at Day 29
The quality of life of participants was evaluated by SF-36 Korean version questionnaire. It is composed of 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Participants answered to the questionnaire of 36 questions; and physical, social, and psychological health status were assessed. It ranges 0 to 100, and higher score indicates better quality of life, But in "Reported (Rptd.) Health Transition" domain higher score indicates worse quality of life.
Time frame: Baseline and Day 29
Change From Baseline in Oswestry Disability Index (ODI) Korean Version Score at Day 29
The ODI Korean version was used to assess the participant's functionality. The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). Total score is the sum of score obtained in each section and ranges from 0 to 50. A higher score represents greater disability.
Time frame: Baseline and Day 29
Percentage of Participants With Investigator's Global Assessment on Investigational Product
Global assessment on investigational product was done by investigator on how well the investigational product controlled chronic (lasting a long time) low back pain. Assessment was done by categories 'Very bad (-2)' 'Bad (-1)' 'Not changed (0) 'Good (1)' and 'Very good (2)'. Assessment better than "Good" was considered as pain improvement success. Percentage of participants with pain improvement success is reported here.
Time frame: Day 29
Percentage of Participants With Participants' Global Assessment on Investigational Product
Global assessment on investigational product was done by participants on how well the investigational product controlled chronic (lasting a long time) low back pain. Assessment was done by categories 'Very bad (-2)' 'Bad (-1)' 'Not changed (0) 'Good (1)' and 'Very good (2)'. Assessment better than "Good" was considered as pain improvement success. Percentage of participants with pain improvement success is reported here.
Time frame: Day 29
| Milestone | Tramadol HCl/Acetaminophen | Placebo |
|---|---|---|
| Started | 126 | 122 |
| Treated | 125 | 120 |
| Completed | 92 | 104 |
| Not completed | 34 | 18 |
| Withdrew: Adverse event | 24 | 6 |
| Withdrew: Withdrawal by subject | 3 | 5 |
| Withdrew: Protocol violation | 5 | 3 |
| Withdrew: Participants not compliant | 1 | 2 |
| Withdrew: Participants not receive any study drug | 1 | 2 |
The percentage of participants with extent of reduction in pain intensity greater than or equal to 30 percent was reported. Pain intensity change rate was calculated by Visual Analog Scale (VAS) score at baseline minus VAS score at Day 29 divided by VAS score at Baseline. VAS is a 10 centimeter (cm) scale. Intensity of pain range: 0 cm=no pain to 10 cm=worst possible pain.
| Percentage of Participants | Tramadol HCl/Acetaminophen | Placebo |
|---|---|---|
| Percentage of Participants With Reduction in Pain Intensity | 57.65 (47.14 to 68.15) | 41.11 (30.95 to 51.28) |
Change in pain intensity experienced by participants over the last 48 hours was measured on Day 29 against Baseline with VAS. VAS is a 10 cm scale. Intensity of pain range: 0 cm=no pain to 10 cm=worst possible pain.
| Unit on a scale | Tramadol HCl/Acetaminophen | Placebo |
|---|---|---|
| Baseline | 6.334 ± 1.383 | 6.000 ± 1.331 |
| Change at Day 29 | 2.299 ± 1.764 | 1.549 ± 1.578 |
Pain relief was measured in 6 stages to assess the participant's pain relief. Extent of pain relief was measured on a scale ranging from 4 to -1, where 4=complete disappearance, 3=fair relief, 2=moderate relief, 1=slight relief, 0=no change and -1=pain worsening. Relief more than 'slight relief (1)' was considered as pain relief success.
| Percentage of participants | Tramadol HCl/Acetaminophen | Placebo |
|---|---|---|
| Day 8: Slight relief (n=82,88) | 70.73 (60.88 to 80.58) | 53.41 (42.99 to 63.83) |
| Day 15: Slight relief (n=85,89) | 82.35 (74.25 to 90.46) | 65.17 (55.27 to 75.07) |
| Day 29, Slight relief (85,89) | 81.18 (72.87 to 89.49) | 77.53 (68.86 to 86.20) |
The quality of life of participants was evaluated by SF-36 Korean version questionnaire. It is composed of 8 domains: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. Participants answered to the questionnaire of 36 questions; and physical, social, and psychological health status were assessed. It ranges 0 to 100, and higher score indicates better quality of life, But in "Reported (Rptd.) Health Transition" domain higher score indicates worse quality of life.
| Unit on a scale | Tramadol HCl/Acetaminophen | Placebo |
|---|---|---|
| Baseline: Physical functioning | 46.71 ± 20.71 | 47.94 ± 20.80 |
| Change at Day 29: Physical functioning (n=83,87) | 9.82 ± 18.35 | 6.67 ± 15.99 |
| Baseline: Role physical | 44.93 ± 24.18 | 49.51 ± 26.17 |
| Change at Day 29: Role Physical (n=83,87) | 16.04 ± 23.89 | 8.69 ± 22.62 |
| Baseline: Bodily pain | 34.66 ± 14.46 | 35.99 ± 13.89 |
| Change at Day 29: Bodily pain (n=83,87) | 19.39 ± 18.99 | 17.69 ± 14.84 |
| Baseline: General health | 43.56 ± 17.92 | 48.11 ± 17.05 |
| Change at Day 29: General health (n=83,87) | 7.36 ± 14.41 | 2.77 ± 12.58 |
| Baseline: Vitality | 38.82 ± 19.93 | 42.71 ± 17.83 |
| Change at Day 29: Vitality (n=83,87) | 11.14 ± 20.55 | 5.82 ± 18.94 |
| Baseline: Social functioning | 64.26 ± 22.59 | 64.58 ± 26.98 |
| Change at Day 29: Social functioning (n=83,87) | 11.75 ± 25.70 | 6.61 ± 20.60 |
| Baseline: Role emotional | 61.76 ± 27.41 | 61.57 ± 29.34 |
| Change at Day 29: Role emotional (n=83,87) | 8.13 ± 28.93 | 7.47 ± 28.25 |
| Baseline: Mental Health | 61.06 ± 19.03 | 60.56 ± 19.34 |
| Change at Day 29: Mental Health (n=83,87) | 20.48 ± 23.20 | 18.39 ± 24.61 |
| Baseline: Rptd. health transition | 65.00 ± 24.76 | 63.61 ± 20.92 |
| Change at Day 29: Rptd. health transition(n=83,87) | -18.07 ± 25.99 | -6.90 ± 30.19 |
The ODI Korean version was used to assess the participant's functionality. The ODI is a low back pain-specific, validated instrument that consists of questions related to limitations in performing specific activities of daily living and 1 question related to pain intensity. The ODI is a self-administered questionnaire consists of 10 sections. Each section consists of 6 statements ranked from 0 to 5 (0=good to 5=worse). Total score is the sum of score obtained in each section and ranges from 0 to 50. A higher score represents greater disability.
| Unit on a scale | Tramadol HCl/Acetaminophen | Placebo |
|---|---|---|
| Baseline | 39.626 ± 12.239 | 38.126 ± 13.518 |
| Change at Day 29 (n=87,83) | 11.216 ± 11.856 | 7.178 ± 13.879 |
Global assessment on investigational product was done by investigator on how well the investigational product controlled chronic (lasting a long time) low back pain. Assessment was done by categories 'Very bad (-2)' 'Bad (-1)' 'Not changed (0) 'Good (1)' and 'Very good (2)'. Assessment better than "Good" was considered as pain improvement success. Percentage of participants with pain improvement success is reported here.
| Percentage of participants | Tramadol HCl/Acetaminophen | Placebo |
|---|---|---|
| Percentage of Participants With Investigator's Global Assessment on Investigational Product | 81.25 (72.70 to 89.80) | 69.88 (60.01 to 79.75) |
Global assessment on investigational product was done by participants on how well the investigational product controlled chronic (lasting a long time) low back pain. Assessment was done by categories 'Very bad (-2)' 'Bad (-1)' 'Not changed (0) 'Good (1)' and 'Very good (2)'. Assessment better than "Good" was considered as pain improvement success. Percentage of participants with pain improvement success is reported here.
| Percentage of participants | Tramadol HCl/Acetaminophen | Placebo |
|---|---|---|
| Percentage of Participants With Participants' Global Assessment on Investigational Product | 76.25 (66.92 to 85.58) | 72.29 (62.66 to 81.92) |
Collected over Baseline up to Day 29. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tramadol HCl/Acetaminophen | — | 1/125 (0.8%) | 102/125 (81.6%) |
| Placebo | — | 0/120 (0%) | 52/120 (43.3%) |
| Event | Tramadol HCl/Acetaminophen | Placebo |
|---|---|---|
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/125 | 0/120 |
| Event | Tramadol HCl/Acetaminophen | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 45/125 | 12/120 |
| DizzinessNervous system disorders | 34/125 | 10/120 |
| ConstipationGastrointestinal disorders | 23/125 | 4/120 |
| VomitingGastrointestinal disorders | 21/125 | 5/120 |
| SomnolenceNervous system disorders | 18/125 | 4/120 |
| PruritusSkin and subcutaneous tissue disorders | 18/125 | 4/120 |
| DyspepsiaGastrointestinal disorders | 13/125 | 12/120 |
| HeadacheNervous system disorders | 11/125 | 6/120 |
| Decreased appetiteMetabolism and nutrition disorders | 6/125 | 4/120 |
| InsomniaPsychiatric disorders | 6/125 | 0/120 |
| Age Continuous(Years) | Tramadol HCl/Acetaminophen | Placebo | Total |
|---|---|---|---|
| Mean | 59.93 ± 10.72 | 60.39 ± 9.87 | 60.16 ± 10.29 |
| Sex: Female, Male(Participants) | Tramadol HCl/Acetaminophen | Placebo | Total |
|---|---|---|---|
| Female | 94 | 89 | 183 |
| Male | 31 | 31 | 62 |
No study locations are listed for this record.
The record gives a start of May 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tramadol · Acetaminophen